Therapeutic effect of canagliflozin combined with sacubitril/valsartan in non-diabetic patients with HFpEF
ZHANG Cunxing
CHEN Junhua
HUANG Weifang
LAN Xiaoyan
Abstract：Objective To observe the effect of canagliflozin combined with oral sacubitril/valsartan in the treat-ment of non-diabetic heart failure with preserved ejection fraction(HFpEF).Methods Seventy non-diabetic HFpEF patients were randomly divided into the observation group and control group,with 35 cases in each group.Patients in the observation group were given canagliflozin(100 mg,once a day)and sacubitril/valsartan(25-200 mg,twice a day)orally on the basis of conventional treatment,while patients in the control group were given sacubitril/valsartan(25-200 mg,twice a day)orally on the basis of conventional treatment.Blood pressure,blood glucose,BMI and uric acid of the two groups were detected before and after treatment.Peripheral venous blood of the two groups were collected before and after treatment,and serum N-terminal brain natriuretic peptide precursor(NT-proBNP),high-sensitive C-reactive pro-tein(hs-CRP)and interleukin-6(IL-6)were detected.Ventricular ejection fraction(LVEF),left atrial diameter(LAD),left ventricular end-diastolic diameter(LVEDD)and E/A values were calculated by echocardiography.The cardiac function was evaluated by New York Heart Association(NYHA)and 6-minute walking test.The therapeutic ef-fect was evaluated according to the improvement of cardiac function.Results Compared with the control group,systol-ic blood pressure and diastolic blood pressure decreased in the observation group after treatment(both P<0.05).Com-pared with those before treatment,the levels of serum NT-proBNP,hs-CRP,and IL-6 decreased in the two groups after treatment,and the decrease was more significant in the observation group(all P<0.05).Compared with those before treatment,the E/A values of both groups increased after treatment,and the increase was more obvious in the observation group(P<0.05).The 6-minute walking distance of the observation group and control group increased after treatment in comparison with that before treatment(P<0.05).Compared with the control group,the observation group had a longer 6-minute walking distance after treatment(P<0.05).The improvement of cardiac function in the observation group was higher than that in the control group(P<0.05).Conclusion Canagliflozin combined with oral sacubitril/valsartan is effective in the treatment of non-diabetic HFpEF,and can significantly improve the cardiac function of patients through the mechanisms such as lowering blood pressure,reducing the preload and afterload of the heart,preventing or reversing myocardial remodeling.
Keywords：canagliflozinsacubitril/valsartanheart failureheart failure with preserved ejection fraction
Publication Date：2025-01-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 10-14 )